Targeted therapy for non-small cell lung cancer.
The overall survival for the treatment of lung cancer patients is less than 15%, despite advances in chemotherapy, radiation therapy, and surgery, due to the inability to control metastatic disease. Over the past three decades, the genetics of lung cancer has been progressively delineated. Small molecule drugs or monoclonal antibodies have been developed that target and inactivate specific cancer-related proteins, such as growth factor receptors or their kinases. This article will review the therapeutic implications of molecular changes associated with non-small cell lung cancer and the status of targeted therapies in its treatment.
Toloza
Eric M
EM
Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA. toloz001@mc.duke.edu
D'Amico
Thomas A
TA
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D016328:NF-kappa B / Q000037:antagonists & inhibitors; D016283:Proto-Oncogene Proteins p21(ras) / Q000037:antagonists & inhibitors; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors
D000970:Antineoplastic Agents; D016328:NF-kappa B; D066246:ErbB Receptors; D040262:Receptors, Vascular Endothelial Growth Factor; D016283:Proto-Oncogene Proteins p21(ras)